Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2026)

Denali Therapeutics has reported Accumulated Expenses over the past 9 years, most recently at $95.0 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 4.34% to $95.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.0 million through Dec 2025, up 4.34% year-over-year, with the annual reading at $95.0 million for FY2025, 4.34% up from the prior year.
  • Accumulated Expenses was $95.0 million for Q4 2025 at Denali Therapeutics, up from $4.9 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $95.0 million in Q4 2025 and troughed at $4.8 million in Q3 2024.
  • The 5-year median for Accumulated Expenses is $8.2 million (2022), against an average of $23.1 million.
  • Year-over-year, Accumulated Expenses surged 250.77% in 2022 and then crashed 70.45% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $19.0 million in 2021, then surged by 250.77% to $66.7 million in 2022, then increased by 2.71% to $68.5 million in 2023, then surged by 32.95% to $91.1 million in 2024, then increased by 4.34% to $95.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Accumulated Expenses are $95.0 million (Q4 2025), $4.9 million (Q3 2025), and $7.0 million (Q2 2025).